AroCell AB (publ) (AROC.ST)
SEK 0.57
(0.0%)
SEK 0.57
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -2.1 Million SEK | 0.14% |
| 2022 | -2.1 Million SEK | 58.28% |
| 2021 | -5.04 Million SEK | -8107.94% |
| 2020 | 63 Thousand SEK | -10.65% |
| 2019 | 70.5 Thousand SEK | 115.01% |
| 2018 | -469.7 Thousand SEK | -307.94% |
| 2017 | 225.88 Thousand SEK | 313.66% |
| 2016 | 54.6 Thousand SEK | -88.13% |
| 2015 | 460.21 Thousand SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 100.0% |
| 2012 | -15.12 Thousand SEK | 0.0% |
| 2011 | - SEK | -100.0% |
| 2010 | 26.85 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 2.82 Million SEK | 227.07% |
| 2024 Q3 | 3.07 Million SEK | 10.95% |
| 2024 Q2 | 2.77 Million SEK | -1.8% |
| 2023 FY | -2.1 Million SEK | 0.14% |
| 2023 Q3 | 775 Thousand SEK | 240.91% |
| 2023 Q2 | -550 Thousand SEK | -667.01% |
| 2023 Q4 | -2.22 Million SEK | -386.97% |
| 2023 Q1 | 97 Thousand SEK | -88.47% |
| 2022 Q1 | -1.1 Million SEK | 49.91% |
| 2022 Q4 | 841 Thousand SEK | -38.39% |
| 2022 Q3 | 1.36 Million SEK | 149.89% |
| 2022 Q2 | -2.73 Million SEK | -148.05% |
| 2022 FY | -2.1 Million SEK | 58.28% |
| 2021 Q1 | 8000.00 SEK | -60.0% |
| 2021 Q3 | -2.85 Million SEK | -57180.0% |
| 2021 Q4 | -2.2 Million SEK | 22.85% |
| 2021 FY | -5.04 Million SEK | -8107.94% |
| 2021 Q2 | 5000.00 SEK | -37.5% |
| 2020 Q1 | 43 Thousand SEK | 149.71% |
| 2020 Q4 | 20 Thousand SEK | 0.0% |
| 2020 FY | 63 Thousand SEK | -10.65% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q2 | - SEK | -100.0% |
| 2019 Q4 | -86.49 Thousand SEK | -266.33% |
| 2019 Q3 | 52 Thousand SEK | -21.21% |
| 2019 FY | 70.5 Thousand SEK | 115.01% |
| 2019 Q1 | 40 Thousand SEK | 13598.63% |
| 2019 Q2 | 66 Thousand SEK | 65.0% |
| 2018 Q1 | - SEK | -100.0% |
| 2018 Q2 | -355 Thousand SEK | 0.0% |
| 2018 FY | -469.7 Thousand SEK | -307.94% |
| 2018 Q4 | 292.00 SEK | 100.26% |
| 2018 Q3 | -114 Thousand SEK | 67.89% |
| 2017 Q4 | 4885.00 SEK | 0.0% |
| 2017 FY | 225.88 Thousand SEK | 313.66% |
| 2017 Q3 | - SEK | -100.0% |
| 2017 Q2 | 165 Thousand SEK | 194.64% |
| 2017 Q1 | 56 Thousand SEK | 221.74% |
| 2016 FY | 54.6 Thousand SEK | -88.13% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 Q3 | 46 Thousand SEK | 0.0% |
| 2016 Q4 | -46 Thousand SEK | -200.0% |
| 2015 FY | 460.21 Thousand SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 Q4 | 460.21 Thousand SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 FY | - SEK | 100.0% |
| 2013 Q1 | - SEK | 100.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2012 Q1 | - SEK | -100.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q4 | -15.12 Thousand SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 FY | -15.12 Thousand SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 FY | - SEK | -100.0% |
| 2011 Q1 | - SEK | -100.0% |
| 2011 Q4 | 2000.00 SEK | 0.0% |
| 2010 Q3 | - SEK | 0.0% |
| 2010 Q2 | - SEK | 0.0% |
| 2010 Q4 | 13.85 Thousand SEK | 0.0% |
| 2010 FY | 26.85 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | 148.1 Million SEK | 101.419% |
| Immunovia AB (publ) | -5.1 Million SEK | 58.841% |
| Prostatype Genomics AB (publ) | -18.09 Million SEK | 88.38% |
| SenzaGen AB | 34.93 Million SEK | 106.017% |
| Spermosens AB | -169 Thousand SEK | -1143.787% |